Clinical trials: Obese With Comorbidities
Obesity
A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland
The study is intended to understand the distribution of different obesity classes and obesity related diseases (diseases that present along with obesity) in patients with body mass index (BMI) ≥ 30 kg/m^2.
- Trial name
- ExplorEUEast (NCT05795166)
- Testing
- No treatment given
- Volunteers
- 1,241 people
- Sponsor
- Novo Nordisk A/S
Asthma Bronchiale, Breast Neoplasms
Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity
The web application gp-multitool.de is a digital tool for implementing the German S3 clinical practice guideline for multimorbidity of the German Society of General Practitioners and Family Physicians in primary care.
- Conditions
- Asthma Bronchiale, Breast Neoplasms, Coronary Disease, Diabetes Mellitus, Type 2
- Trial name
- NCT06831994
- Testing
- gp-multitool.de
- Where
- Germany
- Volunteers
- 659 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Obesity, Overweight
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related…
- Trial name
- NCT07497880
- Testing
- KAI-7535
- Where
- 36 sites in United States, Australia
- Volunteers
- 306 people
- Sponsor
- Kailera
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay
This is a Phase 4 observational study evaluating the safety and effectiveness of tirzepatide (T.G.) manufactured by INDUFAR S.A.
- Conditions
- Obesity, Type 2 Diabetes Mellitus, Overweight With Comorbidities
- Trial name
- NCT07492563
- Testing
- Tirzepatide (T.G.)
- Where
- Paraguay
- Volunteers
- 300 people
- Sponsor
- LABORATORIOS INDUFAR
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Morbid Obesity
Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities
Morbid obesity is an increasing medical problem in the western countries. It's related to comorbidities as diabetes mellitus, hypertension, OSAS, arthrosis and hypercholesterolemia.
- Trial name
- Elegance (NCT01686997)
- Testing
- Roux-en-Y Gastric Bypass
- Where
- Netherlands
- Volunteers
- 280 people
- Sponsor
- Rijnstate Hospital
NAFLD, Obesity
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2…
- Conditions
- NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias
- Trial name
- NCT05872269
- Testing
- Saroglitazar
- Where
- 19 sites in India
- Volunteers
- 1,500 people
- Sponsor
- Zydus Lifesciences Limited
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
AIM-WEIGHT is a clinical study evaluating whether a fixed microbiome-targeted nutritional supplement can support weight loss in adults with overweight or obesity who do not have prediabetes or diabetes.
- Trial name
- AIM-WEIGHT (NCT07736547)
- Testing
- AI-Guided Microbiome-Targeted Nutritional Supplement, Lifestyle counselling
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Varol TUNALI
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company